CBIO

Crescent Biopharma Stock Analysis

AI Rating

Fair
  • Quality1/10
  • Growth↑ 8/10
  • Momentum↓ 1/10
Crescent Biopharma sales and earnings growth
CBIO Growth
Good
  • Revenue Y/Y↓ -100.00%
  • EPS Y/Y↑ 65.81%
  • FCF Y/Y↓ -40.45%
Crescent Biopharma gross and profit margin trends
CBIO Profitability
Low
  • Gross margin ↓ 0.00%
  • EPS margin↓ 0.00%
  • ROIC↓ -9171.10%
Crescent Biopharma net debt vs free cash flow
CBIO Risk
Great
  • Debt / Equity↓ 0.0
  • Debt / FCF↓ 0.0
  • Interest coverage↓ -51.2

Crescent Biopharma stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗